NONALCOHOLIC STEATOHEPATITIS

This study looked at whether vitamin E can help adults with nonalcoholic fatty liver disease (NAFLD). Researchers tested different doses of vitamin E in 200 people to see which dose best lowers liver enzymes. The goal is to find a safe and effective dose to control the disease.

This study tested whether two drugs—semaglutide and a combination of cilofexor and firsocostat—could reduce liver scarring in people with advanced liver disease (cirrhosis) caused by NASH. About 457 participants took one or both drugs or a placebo for 72 weeks. The goal was to se…

This study tested a new medicine called AZD2693 in 220 adults with a type of fatty liver disease (NASH) that includes liver scarring. Only people with a specific gene variant (PNPLA3 148M) that raises their risk were included. The goal was to see if the drug could reverse the liv…

This study tested a new medicine called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. The main goal was to see if the drug could stop signs of NASH without making liver scarring worse. Researchers also checked for side effects …

This study tested a drug called saroglitazar magnesium in 189 adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis. The goal was to see if the drug could reduce liver inflammation and scarring without making the disease worse. Participants were randomly assigned to …

This study followed over 7,300 people with nonalcoholic fatty liver disease (NAFLD) or its more severe form, NASH, in regular medical clinics. The goal was to learn how the disease progresses over time and how doctors currently treat it, since there are no approved medications. T…